Pomanda estimates the enterprise value of GENESIS BIOSCIENCES LIMITED at £1.2m based on a Turnover of £1m and 1.14x industry multiple (adjusted for size and gross margin).
genesis biosciences limitedEstimated Valuation
£407.8k
Pomanda estimates the enterprise value of GENESIS BIOSCIENCES LIMITED at £407.8k based on an EBITDA of £89.4k and a 4.56x industry multiple (adjusted for size and gross margin).
genesis biosciences limitedEstimated Valuation
£1m
Pomanda estimates the enterprise value of GENESIS BIOSCIENCES LIMITED at £1m based on Net Assets of £657k and 1.59x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Genesis Biosciences LimitedOverview
Genesis Biosciences Limited is a live company located in cardiff, CF3 2PU with a Companies House number of 05723829. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in February 2006, it's largest shareholder is
genesis bioscience llc
with a 100% stake. Genesis Biosciences Limited is a established,
small sized company, Pomanda has estimated its turnover at
£1m with
low
growth in recent years.
Pomanda's financial health check has awarded Genesis Biosciences Limited a 3 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 6 areas for improvement. Company Health Check FAQs
Health Rating3out of 5
2 Strong
2 Regular
6 Weak
Size
annual sales of £1m, make it smaller than the average company (£4.5m)
£1m - Genesis Biosciences Limited
£4.5m - Industry AVG
Growth
3 year (CAGR) sales growth of 3%, show it is growing at a slower rate (13.1%)
3% - Genesis Biosciences Limited
13.1% - Industry AVG
Production
with a gross margin of 53.9%, this company has a comparable cost of product (53.9%)
53.9% - Genesis Biosciences Limited
53.9% - Industry AVG
Profitability
an operating margin of 7.5% make it more profitable than the average company (-4.1%)
7.5% - Genesis Biosciences Limited
-4.1% - Industry AVG
Employees
with 11 employees, this is below the industry average (54)
11 - Genesis Biosciences Limited
54 - Industry AVG
Pay Structure
on an average salary of £83k, the company has an equivalent pay structure (£83k)
£83k - Genesis Biosciences Limited
£83k - Industry AVG
Efficiency
resulting in sales per employee of £92.9k, this is less efficient (£131.4k)
£92.9k - Genesis Biosciences Limited
£131.4k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Genesis Biosciences Limited
- - Industry AVG
Creditor Days
its suppliers are paid after 8 days, this is quicker than average (60 days)
8 days - Genesis Biosciences Limited
60 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Genesis Biosciences Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities
for 84 weeks, this is more cash available to meet short term requirements (30 weeks)
84 weeks - Genesis Biosciences Limited
30 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 59.4%, this is a higher level of debt than the average (53.1%)
59.4% - Genesis Biosciences Limited
53.1% - Industry AVG
GENESIS BIOSCIENCES LIMITED financials
EXPORT
Genesis Biosciences Limited's latest turnover from December 2023 is £1 million and the company has net assets of £657 thousand. According to their latest financial statements, Genesis Biosciences Limited has 11 employees and maintains cash reserves of £1.6 million as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Dec 2016
Dec 2015
Dec 2014
Dec 2013
Dec 2012
Dec 2011
Dec 2010
Dec 2009
Turnover
1,021,800
1,028,294
953,122
930,790
787,044
776,106
799,589
370,480
778,812
654,099
705,245
662,288
398,004
383,550
379,750
Other Income Or Grants
Cost Of Sales
471,416
489,381
468,689
445,752
397,868
382,194
409,888
196,145
417,819
342,280
382,133
362,173
224,651
1,245
533
Gross Profit
550,384
538,914
484,433
485,038
389,176
393,912
389,700
174,335
360,993
311,819
323,112
300,115
173,353
382,305
379,217
Admin Expenses
473,764
493,857
432,061
406,376
324,581
339,236
329,472
112,545
305,861
266,341
266,918
252,098
154,044
352,168
369,868
Operating Profit
76,620
45,057
52,372
78,662
64,595
54,676
60,228
61,790
55,132
45,478
56,194
48,017
19,309
30,137
9,349
Interest Payable
961
2,331
4,343
5,657
Interest Receivable
1,879
182
45
290
229
190
104
1,266
3
Pre-Tax Profit
76,620
46,936
52,554
78,706
64,885
54,905
60,417
61,894
47,991
45,040
56,194
48,322
16,978
25,794
3,695
Tax
-18,137
-8,918
-9,985
-14,954
-12,328
-10,432
-11,479
-12,379
-3,794
-9,072
-6,114
-9,075
-4,970
-6,307
-42
Profit After Tax
58,483
38,018
42,569
63,752
52,557
44,473
48,938
49,515
44,197
35,968
50,080
39,247
12,008
19,487
3,653
Dividends Paid
Retained Profit
58,483
38,018
42,569
63,752
52,557
44,473
48,938
49,515
44,197
35,968
50,080
39,247
12,008
19,487
3,653
Employee Costs
913,324
859,546
859,340
774,938
684,091
678,321
608,415
461,573
438,199
394,218
426,061
426,205
268,263
259,043
Number Of Employees
11
11
11
11
10
10
10
8
8
7
8
8
5
5
EBITDA*
89,364
57,946
65,382
91,372
77,579
71,505
75,973
75,408
70,665
66,888
78,750
67,411
38,048
53,311
31,860
* Earnings Before Interest, Tax, Depreciation and Amortisation
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Dec 2016
Dec 2015
Dec 2014
Dec 2013
Dec 2012
Dec 2011
Dec 2010
Dec 2009
Tangible Assets
23,006
31,477
25,133
13,706
20,584
18,142
20,421
29,849
34,023
47,586
64,459
65,915
72,501
88,218
108,201
Intangible Assets
Investments & Other
Debtors (Due After 1 year)
3,191
16,000
16,000
16,000
16,000
16,000
16,000
Total Fixed Assets
23,006
31,477
25,133
13,706
23,775
18,142
20,421
29,849
34,023
63,586
80,459
81,915
88,501
104,218
124,201
Stock & work in progress
Trade Debtors
5,271
221,457
208,526
129,161
87,375
85,032
77,737
Group Debtors
631,636
635,848
535,020
462,679
421,277
420,627
366,925
267,045
Misc Debtors
34,205
58,747
32,492
32,886
28,642
20,300
39,521
22,861
33,299
30,972
27,941
27,781
30,150
20,942
17,129
Cash
1,560,607
13,909
93,446
52,151
37,059
40,224
20,853
54,972
27,918
17,601
2,656
9,445
12,462
7,719
8,675
misc current assets
total current assets
1,594,812
704,292
761,786
620,057
528,380
481,801
481,001
450,029
328,262
270,030
239,123
166,387
129,987
113,693
103,541
total assets
1,617,818
735,769
786,919
633,763
552,155
499,943
501,422
479,878
362,285
333,616
319,582
248,302
218,488
217,911
227,742
Bank overdraft
Bank loan
Trade Creditors
11,338
16,588
13,290
16,596
13,034
17,739
29,818
19,917
36,526
27,154
33,135
15,918
20,504
13,836
10,159
Group/Directors Accounts
739,254
44,000
44,000
44,000
44,000
44,000
44,000
44,000
44,000
50,000
50,000
other short term finances
15,859
23,826
20,751
hp & lease commitments
2,184
2,184
7,029
other current liabilities
206,697
71,032
166,273
52,590
40,937
34,792
68,670
104,913
17,751
88,164
97,495
85,984
27,737
19,360
71,868
total current liabilities
957,289
131,620
223,563
113,186
97,971
96,531
142,488
168,830
98,277
115,318
132,814
104,086
114,100
107,022
109,807
loans
15,357
38,756
hp & lease commitments
2,184
Accruals and Deferred Income
other liabilities
5,369
provisions
3,523
5,626
2,851
2,641
1,785
1,780
2,832
5,307
3,794
5,941
8,207
6,732
6,806
6,860
total long term liabilities
3,523
5,626
2,851
2,641
1,785
1,780
2,832
5,307
3,794
5,941
10,391
12,101
22,163
45,616
total liabilities
960,812
137,246
226,414
115,827
97,971
98,316
144,268
171,662
103,584
119,112
138,755
114,477
126,201
129,185
155,423
net assets
657,006
598,523
560,505
517,936
454,184
401,627
357,154
308,216
258,701
214,504
180,827
133,825
92,287
88,726
72,319
total shareholders funds
657,006
598,523
560,505
517,936
454,184
401,627
357,154
308,216
258,701
214,504
180,827
133,825
92,287
88,726
72,319
Dec 2023
Dec 2022
Dec 2021
Dec 2020
Dec 2019
Dec 2018
Dec 2017
Dec 2016
Dec 2015
Dec 2014
Dec 2013
Dec 2012
Dec 2011
Dec 2010
Dec 2009
Operating Activities
Operating Profit
76,620
45,057
52,372
78,662
64,595
54,676
60,228
61,790
55,132
45,478
56,194
48,017
19,309
30,137
9,349
Depreciation
12,744
12,889
13,010
12,710
12,984
16,829
15,745
13,618
15,533
21,410
22,556
19,394
18,739
23,174
22,511
Amortisation
Tax
-18,137
-8,918
-9,985
-14,954
-12,328
-10,432
-11,479
-12,379
-3,794
-9,072
-6,114
-9,075
-4,970
-6,307
-42
Stock
Debtors
-656,178
22,043
100,434
73,394
52,935
-18,571
65,091
94,713
31,915
15,962
79,525
39,417
11,551
11,108
110,866
Creditors
-5,250
3,298
-3,306
3,562
-4,705
-12,079
9,901
-16,609
9,372
-5,981
17,217
-4,586
6,668
3,677
10,159
Accruals and Deferred Income
135,665
-95,241
113,683
11,653
6,145
-33,878
-36,243
87,162
-70,413
-9,331
11,511
58,247
8,377
-52,508
71,868
Deferred Taxes & Provisions
-2,103
2,775
210
2,641
-1,785
5
-1,052
-2,475
1,513
-2,147
-2,266
1,475
-74
-54
6,860
Cash flow from operations
855,717
-62,183
65,550
20,880
11,971
33,692
-27,991
36,394
-24,572
24,395
19,573
74,055
36,498
-12,989
9,839
Investing Activities
capital expenditure
-4,273
-19,233
-24,437
-5,832
-15,426
-14,550
-6,317
-9,444
-1,970
-4,537
-21,100
-12,808
-3,022
-3,191
-130,712
Change in Investments
cash flow from investments
-4,273
-19,233
-24,437
-5,832
-15,426
-14,550
-6,317
-9,444
-1,970
-4,537
-21,100
-12,808
-3,022
-3,191
-130,712
Financing Activities
Bank loans
Group/Directors Accounts
695,254
44,000
-50,000
50,000
Other Short Term Loans
-15,859
-7,967
3,075
20,751
Long term loans
-15,357
-23,399
38,756
Hire Purchase and Lease Commitments
-2,184
-2,184
4,368
-7,029
7,029
other long term liabilities
-5,369
5,369
share issue
-2,291
-3,078
2,291
-8,447
-3,080
68,666
interest
1,879
182
45
290
229
190
104
305
-2,331
-4,343
-5,654
cash flow from financing
695,254
1,879
182
45
290
229
190
104
44,000
-4,475
-5,262
-64,264
-28,733
15,224
129,548
cash and cash equivalents
cash
1,546,698
-79,537
41,295
15,092
-3,165
19,371
-34,119
27,054
10,317
14,945
-6,789
-3,017
4,743
-956
8,675
overdraft
change in cash
1,546,698
-79,537
41,295
15,092
-3,165
19,371
-34,119
27,054
10,317
14,945
-6,789
-3,017
4,743
-956
8,675
genesis biosciences limited Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for genesis biosciences limited. Get real-time insights into genesis biosciences limited's credit score, group structure and payment trends.
Perform a competitor analysis for genesis biosciences limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other small companies, companies in CF3 area or any other competitors across 12 key performance metrics.
genesis biosciences limited Ownership
GENESIS BIOSCIENCES LIMITED group structure
Genesis Biosciences Limited has no subsidiary companies.
Ultimate parent company
GENESIS BIOSCIENCES LLC
#0109071
1 parent
GENESIS BIOSCIENCES LIMITED
05723829
GENESIS BIOSCIENCES LIMITED Shareholders
The sole shareholder of Genesis Biosciences Limited is Genesis Bioscience Llc.
genesis bioscience llc
100%
genesis biosciences limited directors
Genesis Biosciences Limited currently has 1 director, Mr Conrad Mielcuszny serving since Feb 2006.
72110 - Research and experimental development on biotechnology
incorporation date
February 2006
age
19
incorporated
UK
ultimate parent company
GENESIS BIOSCIENCES LLC
accounts
Small Company
last accounts submitted
December 2023
previous names
biotal technologies limited (September 2009)
accountant
-
auditor
DSJ PARTNERS (UK) LIMITED
address
unit p1, capital business park, capital point, parkway, cardiff, CF3 2PU
Bank
-
Legal Advisor
-
genesis biosciences limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to genesis biosciences limited.
genesis biosciences limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for GENESIS BIOSCIENCES LIMITED. This can take several minutes, an email will notify you when this has completed.
genesis biosciences limitedCompanies House Filings - See Documents
